A fully integrated CRAMS player working with global pharmaceutical innovators. We have a global presence with development and manufacturing facilities across Europe, India, and China. We provide end-to-end, integrated, high-value, niche CRAMS offering, right from process research & development to late-stage clinical and commercial manufacturing facilities along with the supply of Active Pharmaceutical Ingredients (API) to innovator pharmaceutical companies.
To put it in short Dishman is the BCG of Pharma Sector
CMP 210 against a book value 298. The stock is beaten down due to poor India performance in FY 20-21 due to approval issues in it Bavla plant. However management is confident that in Fy 21-22 indian operations can return to Fy 19-20 levels.
They have many molecules in pipeline and good orders on hand.
Rakesh JJ & Mukul agarwal hold around 5.43% of the company.
With the pharma boom this one is surely underpriced.
.